Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia
Richard M. Stone(Dana-Farber Cancer Institute), Anand Patel(Ascension), Maximilian Stahl(Harvard University), Marina Konopleva(Albert Einstein College of Medicine), Anthony Letai(Dana-Farber Cancer Institute), Marlise R. Luskin(Dana-Farber Cancer Institute), Geoffrey Fell(Dana-Farber Cancer Institute), Rebecca Leonard(Dana-Farber Cancer Institute), Martha Wadleigh(Dana-Farber Cancer Institute), Evan C. Chen(Dana-Farber Cancer Institute), Ilene Galinsky(Dana-Farber Cancer Institute), Jeremy Ryan(Dana-Farber Cancer Institute), Yael Flammand(Dana-Farber Cancer Institute), Virginia O. Volpe(UConn Health), Hunter Smith(Dana-Farber Cancer Institute), Howard Weiner(NYU Langone Health), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Lexi Noyes(Dana-Farber Cancer Institute), Eric S. Winer(Providence College)
Cited by 1
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k